| This paper is composed of two parts.The first part elaborates the medication rules of the method of soothing the liver and strengthening the spleen in the treatment of hepatitis B liver fibrosis through literature research,and the second part observes the clinical efficacy evaluation of the method of soothing the liver and strengthening the spleen in the treatment of hepatitis b liver fibrosis under the guidance of "he" theory through clinical research.Part 1ObjectiveThis paper summarizes the medication rules of the method of soothing the liver and strengthening the spleen in the treatment of hepatitis B liver fibrosis through literature research.MethodsUsing"China National Knowledge Infrastructure","Weipu Chinese Journals Database",and "Wanfang Medical Network" as the search database,the literatures on the treatment of liver hepatitis B fibrosis using the method of relieving liver and spleen from December 2008 to October 2019 were retrieved.A search was conducted to establish a database for the treatment of liver fibrosis by spleen-relieving and strengthening the spleen,using cluster analysis and association rules to explore and analyze the medication rules for the method of relieving liver-spleen and strengthening the spleen to treat hepatitis-B fibrosis.ResultsA total of 66 qualified literatures were included,involving 126 flavors of single Chinese medicine,The top four drug types are tonic deficiency medicine,blood circulation promoting stasis medicine,qi regulating medicine,and diuretic and damp dampening medicine.The cumulative frequency of the four types of drugs accounts for 80.23%.Cluster analysis can be used to find two compatibility rules:1.Yiqi Jianpi combined with Shugan Qiqi medicine,Shaozu nourishing blood and softening liver medicine,2.Yiqi Huoxue combined with Ruanjian Sanjie medicine,Shao Zuo Qi medicine;can be found by association rules The common medicine pair is Chaihu with Bai ji,Chaihu with Atractylodes.ConclusionShugan Jianpi method is often used to treat liver fibrosis of hepatitis B.Shugan liqi medicine,Yiqi Jianpi medicine,Huoxue Huayu medicine and Lishui Shenshi medicine are often used.However,the different stages of liver fibrosis have different emphasis.Part 2ObjectiveThe therapeutic advantages of Heheshuyangfang established by the"Shuganjianpi" method under the guidance of the "He" theory were discussed.Hepatitis B liver fibrosis provides evidence-based medicine and provides new ideas for the next step of clinical research on the prevention and treatment of hepatitis B liver fibrosis with traditional Chinese medicine.MethodsIn this study,a prospective randomized control method was used to select 1:1 hepatitis B liver fibrosis patients from May 1st,2018 to January 1st,2019 in the outpatient and inpatient department of Guangdong Traditional Chinese Medicine Hospital.Randomized proportions were divided into treatment group and control group,50 cases each.Among them,the control group was given entecavir antiviral treatment,and the treatment group was combined with Heshuyangfang treatment based on the entecavir treatment in the control group.The LSM value,liver pathology,APFI score,FIB-4 score,liver fiber 4 were observed before and after treatment in the two groups Items,imaging scores,liver function recovery,HBV-DNA negative rate,two half of hepatitis B,TCM syndrome scores are different.Results1.In terms of improvement of LSM value,the treatment group was statistically more significant than the control group at week 48(P<0.05),and there was no statistical significance before the follow-up(P>0.05);comparison within the group found that each group was followed up Nodal and baseline levels were statistically significant(P<0.05);2.On the APRI and FIB-4 scores,the APRI scores at each time node and the control group were not statistically significant(P>0.05),within the group comparison it was found that the ratio of follow-up nodes to baseline levels in both groups was statistically significant(P<0.05),and the FIB-4 score at each time node was not statistically significant compared with the control group(P>0.05).The ratio of each follow-up node to baseline level in the treatment group was statistically significant(P<0.05),while the control group was statistically significant compared with the baseline level at week 36(P<0.05);3.Comparison of 4 items in liver fiber on the 12th week,PCⅢ was statistically different from the control group at the 12th week(P<0.05),and the follow-up nodes were not statistically significant compared to the control group(P>0.05).Significance(P>0.05),compared within the group found that two groups of patients The four liver fiber follow-up nodes were statistically significant compared with the baseline level(P<0.05);4.In terms of imaging scores,the treatment group had no statistical significance compared with the control group(P>0.05),but the two groups The follow-up nodes of the patients were statistically significant compared with the baseline level(P<0.05);5.In terms of liver function recovery level and recovery rate,the treatment group was statistically more significant than the control group at week 12(P<0.05),and there was no statistical difference in follow-up nodes(P>0.05).The follow-up nodes were statistically significant compared with the baseline level(P<0.05).The liver function recovery rate was statistically different from that of the control group at the 12th week(P<0.05).At 48 weeks,the liver function of both groups had returned to normal;6.On the rate of HBV-DNA negative conversion,The treatment group had statistical significance at the 12th week of follow-up compared with the control group(P<0.05),and there was no statistically significant difference at the follow-up node(P>0.05);7.On comparison of two and a half in hepatitis B,there is no statistical difference in the negative rate compared with the control group(P>0.05);8.On the TCM syndrome score,the score of the group before treatment was not statistically significant(P>0.05),treatment 48 after the week,it was statistically significant(P<0.05);9.On the safety index,no obvious adverse reactions were seen.ConclusionThis study compared the clinical efficacy of the treatment group with Heshuyangfang combined with entecavir and the control group alone with entecavir in the treatment of hepatitis B liver fibrosis,and reached the following conclusions:1.The use of the Shugan Jianpi method to treat hepatitis B liver fibrosis is outstanding.It is safe and reliable;2.Treatment of liver fibrosis with spleen-healing and spleen-inducing treatment can promote early liver function recovery,HBV-DNA is negative,and has a certain anti-inflammatory and hepatoprotective effect;3.Treating patients with hepatitis B and liver fibrosis with the method of soothe the liver and fortify the spleen can significantly improve the clinical symptoms of patients and improve their quality of life.4.Professor Chi Xiaoling using the theory of "He" to soothe the liver and fortify the spleen to treat hepatitis B fibrosis is worthy of further promotion and application... |
PDF Full Text Request